HelpAcademyLoginJoin us as a Member

VERTEX PHARMACEUTICALS INC

Sign in to save VERTEX PHARMACEUTICALS INC to a watchlist Sign in to set an alert for VERTEX PHARMACEUTICALS INC
Tickers
VRTX
Headquarters
Not recorded
SEC CIK
0000875320
Website
Not recorded

Closing prices

Latest close, 558.88 USD

Closing prices for VRTX250 stored closes for VRTX from 3 Nov 2025 to 30 Oct 2026. Lowest 409.47 on 7 Nov 2025, highest 558.88 on 30 Oct 2026, latest 558.88 on 30 Oct 2026.Close, USD400.00450.00500.00550.00600.003 Nov 20251 May 202630 Oct 2026
250 stored closes, oldest first. End of day, not intraday.

Source: Massive Closing prices as of End-of-day prices, not live

Massive Basic, non-business use; display licence needed before launch (D-1). Marketstack is kept as the backup source.

Not investment advice. End-of-day closing prices, not live quotes.

Drugs

Drugs from VERTEX PHARMACEUTICALS INC
DrugIndicationsPhaseNext catalystCT-VCATrials
CTX001Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save CTX001 to a watchlist Hemoglobinopathies; Beta-Thalassemia; Genetic Diseases, Inborn; Hematologic Diseases; ThalassemiaPhase 3None scheduledNo published CT-VCA score5
PovetaciceptFast Track, Orphan, Accelerated Approval Sign in to save Povetacicept to a watchlist IgA nephropathy (IgAN)FiledPDUFANo published CT-VCA score0
VX-017Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save VX-017 to a watchlist Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe HypoglycemiaPhase 3None scheduledNo published CT-VCA score1
VX-147Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save VX-147 to a watchlist Proteinuric Kidney DiseasePhase 2/3None scheduledNo published CT-VCA score1
VX-880Not yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save VX-880 to a watchlist Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe HypoglycemiaPhase 3None scheduledNo published CT-VCA score1

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

  1. PovetaciceptPDUFA

    · PDUFA date · VERTEX PHARMACEUTICALS INC VRTX

    VERTEX PHARMACEUTICALS INC: PDUFA date in EX-99.1 filed 3 August 2026

    •The U.S. FDA accepted the BLA submission for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026.

    • Fast Track
    • Orphan
    • Accelerated Approval

    Source: 0000875320-26-000256 (opens in a new tab)

    29days to go

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue3,333,900,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)1,099,800,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense993,800,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses2,087,000,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents6,143,500,000 USD At 30 Jun 2026 FY2026 Q210-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities1,708,900,000 USD At 30 Jun 2026 FY2026 Q210-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities7,175,400,000 USD At 30 Jun 2026 FY2026 Q210-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity20,247,900,000 USD At 30 Jun 2026 FY2026 Q210-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)253,460,924 shares At 31 Jul 2026 FY2026 Q210-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Apr 2026 to 30 Jun 2026 FY2026 Q23,333,900,000 USD10-Q filed 4 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2026 to 31 Mar 2026 FY2026 Q12,986,900,000 USD10-Q filed 5 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 FY202512,001,300,000 USD10-K filed 13 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2025 Q33,076,400,000 USD10-Q filed 4 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 FY2026 Q22,964,700,000 USD10-Q filed 4 Aug 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 FY2026 Q12,770,200,000 USD10-Q filed 5 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 FY202511,020,100,000 USD10-K filed 13 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Sep 2024 FY2025 Q32,771,900,000 USD10-Q filed 4 Nov 2025 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read

SEC filings

SEC filings from VERTEX PHARMACEUTICALS INC, newest first
FormFiledWhat it coversDocument
4Event 20 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 22 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000283 (opens in a new tab)
3Event 20 Oct 2026 Initial statement of insider ownership (Form 3) View Initial statement of insider ownership (Form 3) filed 22 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000281 (opens in a new tab)
8-K Current report (8-K)
  • Departure or appointment of directors or officers (Item 5.02)
View Current report (8-K) filed 20 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000278 (opens in a new tab)
4Event 15 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 19 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000276 (opens in a new tab)
4Event 15 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 19 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000274 (opens in a new tab)
4Event 8 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 10 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000272 (opens in a new tab)
3Event 8 Sep 2026 Initial statement of insider ownership (Form 3) View Initial statement of insider ownership (Form 3) filed 10 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000270 (opens in a new tab)
4Event 28 Aug 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 1 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000267 (opens in a new tab)
8-KEvent 27 Aug 2026 Current report (8-K)
  • Departure or appointment of directors or officers (Item 5.02)
View Current report (8-K) filed 1 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000264 (opens in a new tab)
4Event 27 Aug 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 31 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0000875320-26-000261 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Insider transactions

All rows for VERTEX PHARMACEUTICALS INC on Insider Trades

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
4 transactions: grants, exercises, tax withholding, gifts and similar

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.